tiprankstipranks
Aligos Therapeutics presents program updates at APSAL Conference
The Fly

Aligos Therapeutics presents program updates at APSAL Conference

Aligos Therapeutics announced that the company is delivering several oral and poster presentations at the 32nd Conference of the Asian Pacific Association for the Study of the Liver being held Feb 15 – 19 in Taipei, Taiwan at the Taipei International Convention Center. Data is being presented for ALG-055009, Aligos’ THR-beta agonist in clinical development for nonalcoholic steatohepatitis, as well as for several clinical and nonclinical stage investigational agents from its chronic hepatitis B portfolio. "At this year’s meeting, we look forward to sharing data demonstrating that ALG-055009, our thyroid hormone receptor-beta agonist in development for NASH, showed promising anti-lipid effects in subjects with hyperlipidemia," said Lawrence Blatt, Ph.D., MBA, CEO and Chairman of the Board at Aligos. "In addition, we have several presentations which demonstrate the potentially best-in-class antiviral activity of our CAM-E compound, ALG-000184, where notable reductions in HBsAg levels have been observed with higher and longer-term dosing in subjects with HBeAg-positive CHB."

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on ALGS:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles